Valentino A, Fimiani M, Bilenchi R, Castelli A, Francini G, Gonnelli S, Gennari C, Andreassi L
Boll Soc Ital Biol Sper. 1984 Oct 30;60(10):1841-4.
The activity of bromocriptin has been clinically tested on 18 patients suffering from psoriasis. The plasma levels of Human Growth Hormone (HGH), Human Adrenocorticotropic Hormone (ACTH), Thyroid Stimulating Hormone (TSH), Prolactin (PL), Aldosterone and Cortisol were investigated in these 18 patients along with 35 untreated psoriatic patients and 19 normal subjects. Bromocriptin was shown to be effective in 13 of our 18 psoriatic patients. Plasma levels of HGH, ACTH, and Aldosterone, measured in all 53 psoriatic patients, were found to be higher than normal in 11, 26 and 40 patients respectively (HGH and Aldosterone: p less than 0,005; ACTH: p less than 0,001).
已对18名银屑病患者进行了溴隐亭活性的临床试验。在这18名患者以及35名未经治疗的银屑病患者和19名正常受试者中,对人类生长激素(HGH)、人类促肾上腺皮质激素(ACTH)、促甲状腺激素(TSH)、催乳素(PL)、醛固酮和皮质醇的血浆水平进行了研究。在我们的18名银屑病患者中,有13名显示溴隐亭有效。在所有53名银屑病患者中测量的HGH、ACTH和醛固酮的血浆水平,分别在11名、26名和40名患者中高于正常水平(HGH和醛固酮:p<0.005;ACTH:p<0.001)。